HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces

Mycoses

Volumn 53, Issue 6, 2010, Pages 488-494

  Tsang, C S P ^a   Hong, I ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Acrylic; Adhesion; Candida Spp.; HIV; Protease Inhibitors; Secreted Aspartyl Proteinases

Indexed keywords

ACRYLIC ACID; INDINAVIR; RESIN; RITONAVIR; SAQUINAVIR;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; IC 50; IN VITRO STUDY; MICROBIAL ADHESION; NONHUMAN; PRIORITY JOURNAL; SALIVA;

CANDIDA; CANDIDA ALBICANS;

EID: 77958101558     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01743.x     Document Type: Article

References (38)

1. Samaranayake LP, Holmstrup P. Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med 1989; 18: 554-64.
2. Garber GE. Treatment of oral Candida mucositis infections. Drugs 1994; 47: 734-40.
3. Cannon RD, Holmes AP, Mason AB, Monk BC. Oral Candida: clearance, colonization, or candidiasis? J Dent Res 1995; 74: 1152-61.
4. Hube B, Naglik J. Candida albicans proteinases: resolving the mystery of a gene family. Microbiology 2001; 147: 1997-2005.
5. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med 1996; 334: 1674-5.
6. Schmidt-Westhausen A, Priepke F, Bergmann FJ, Reichart PA. Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med 1999; 29: 336-41.
7. Gruber A, Speth C, Lukasser-Vogl E et al. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 1999; 41: 227-34.
8. Borg-von Zepelin M, Meyer I, Thomssen R et al. HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol 1999; 113: 747-51.
9. Bektic J, Lell CP, Fuchs A et al. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. FEMS Immunol Med Microbiol 2001; 31: 65-71.
10. Falkensammer B, Pilz G, Bektić J et al. Absent reduction by HIV protease inhibitors of Candida albicans adhesion to endothelial cells. Mycoses 2007; 50: 172-7.
11. Ellepola AN, Samaranayake LP. Adhesion of oral Candida albicans isolates to denture acrylic following limited exposure to antifungal agents. Arch Oral Biol 1998; 43: 999-1007.
12. Veerman EC, Van Den Keybus PA, Vissink A, Nieuw Amerongen AV. Human glandular salivas: their separate collection and analysis. Eur J Oral Sci 1996; 104: 346-52.
13. Perelson AS, Essunger P, Ho DD. Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS 1997; 11(Suppl. A): S17-24.
14. Clerici M, Stocks NI, Zajac RA et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989; 84: 1892-9.
15. Dolan MJ, Clerici M, Blatt SP et al. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995; 172: 79-87.
16. Collier AC, Coombs RW, Schoenfeld DA et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996; 334: 1011-7.
17. Autran B, Carcelain G, Li TS et al. Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-6.
18. Angel JB, Kumar A, Parato K et al. Improvement in cell-mediated immune functions during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998; 177: 898-904.
19. Wendland T, Furrer H, Vernazza PL et al. HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraema. AIDS 1999; 13: 1857-62.
20. Kitchen VS, Skinner C, Ariyoshi K et al. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345: 952-5.
21. Lewis JS II, Terriff CM, Coulston DR, Garrison MW. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clin Ther 1997; 19: 187-214.
22. Hoegl L, Thomas-Greber E, Röcken M, Korting HC. HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2 year study. Mycoses 1998; 41: 321-5.
23. Korting HC, Schaller M, Eder G, Hamm G, Bohmer U, Hube B. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors Saquinavir and Indinavir on "in vitro" activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother 1999; 43: 2038-42.
24. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277: 145-53.
25. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999; 180: 448-53.
26. Pichová I, Pavlíčková L, Dostál J et al. Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors. Eur J Biochem 2001; 268: 2669-77.
27. Diz Dios P, Otero Varela I, Iglesias Martin I, Ocampo Hermida A, Martinez Vázquez C. Failure of indinavir to inhibit Candida albicansin vitro. Eur J Clin Microbiol Infect Dis 1999; 18: 755-6.
28. Gruber A, Berlit J, Speth C et al. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors. Immunobiology 1999; 201: 133-44.
29. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2008; 33: 307-20.
30. Monod M, Borg-von Zepelin M, Telenti A, Sanglard D. The inhibition of Candida-albicans-secreted aspartic proteinases by three different HIV protease inhibitors. Dermatology 1999; 198: 412-4.
31. Stewart K, Abad-Zapatero C. Candida proteases and their inhibition: prospects for antifungal therapy. Curr Med Chem 2001; 8: 941-8.
32. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996; 51: 701-12.
33. Danner SA, Carr A, Leonard JM et al. A short term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-33.
34. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24 week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996; 10: 485-92.
35. Schaller M, Korting HC, Schäfer W, Bastert J, Chen W, Hube B. Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis. Mol Microbiol 1999; 34: 169-80.
36. Sanglard D, Hube B, Monod M, Odds FC, Gow GA. A triple deletion of the secreted aspartyl proteinase genes SAP4, SAP5, and SAP6 of Candida albicans causes attenuated virulence. Infect Immun 1997; 65: 3539-46.
37. Panagoda GJ, Ellepola AN, Samaranayake LP. Adhesion of Candida parapsilosis to epithelial and acrylic surfaces correlates with cell surface hydrophobicity. Mycoses 2001; 44: 29-35.
38. Jones GW, Isaacson RE. Proteinaceous bacterial adhesins and their receptors. Crit Rev Microbiol 1983; 10: 229-60.